The Office of Therapeutic Products Bets on Communication; New Cell and Gene Therapy Access Model to Be Tested; ASGCT 2023 Policy Summit Analysis (Blast 1/2)

ASGCT 2023 Policy Summit Analysis 1: Cell and gene therapies (CGTs) have emerged as novel treatment options with unique characteristics that differ from previously approved therapies, which has motivated the generation of new regulatory processes and policies. The ASGCT 2023 Policy Summit delved into some of the strategies the FDA is following to keep up with innovation in the CGT field. Celltelligence will publish a two-part series discussing these new approaches and providing insights about their relevance in the cell therapy space. In this first blast, the following topics are covered:  

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.